Ingo Hartung: ABBV-969 Dual-Targeting STEAP1 and PSMA ADC Shows Translational Promise with TOPi Payload
Apr 30, 2025, 03:55

Ingo Hartung: ABBV-969 Dual-Targeting STEAP1 and PSMA ADC Shows Translational Promise with TOPi Payload

Ingo Hartung, Executive Director, Head of Medicinal Chemistry and Drug Design at Merck Healthcare, posted on X:

“Regina Reilly disclosing dual-targeting STEAP1/PSMA ADC ABBV-969 carrying a permeable TOPi payload.
The dual format apparently influencing (at the shown time point) internalization. In vitro/vivo data support the translational rationale for dual targeting.”

More posts featuring AACR25.

Ingo Hartung: ABBV-969 Dual-Targeting STEAP1 and PSMA ADC Shows Translational Promise with TOPi Payload